Get started
Author

Yueqing Feng

Observed names: Y Q Feng, Yue-qing Feng
ORCID: 0009-0007-3334-1927
Observed ORCID: 0009-0007-3334-1927
OpenAlex ID: A5101079198
Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients
2014 · Shu-wei Zhou, Bei-bei Su, et al. · Medical Oncology · 33
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
2025 · Dechuang Jiao, Jianghua Qiao, et al. · Clinical Cancer Research · 7
[Expression of GTF2IP23 in breast cancer and it mediated regulation of GTF2I].
2019 · S W Zhou, B B Su, et al. · PubMed · 3
Abstract PO3-27-12: Dexamethasone is necessary for preventing acute emesis induced by anthracycline/cyclophosphamide chemotherapy (HELEN-009) : a multicenter, randomized, open-labeled phase 3 trial
2024 · Xiuchun Chen, Jiao Dechuang, et al. · Cancer Research · 1
MicroRNA-21a-5p regulates TGF-?1-induced myofibroblast transformation of rabbit keratocytes by targeting Smad7
2021 · Jianhai Bai, Minli Zhang, et al. · ScienceAsia · 1
PDF
Data from Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
2025 · Dechuang Jiao, Jianghua Qiao, et al.
Supplementary Figure S1 from Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
2025 · Dechuang Jiao, Jianghua Qiao, et al.
PDF
Supplementary Table S2 from Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
2025 · Dechuang Jiao, Jianghua Qiao, et al.
Supplementary Table S3 from Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
2025 · Dechuang Jiao, Jianghua Qiao, et al.
Supplementary Table S1 from Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
2025 · Dechuang Jiao, Jianghua Qiao, et al.
Abstract PO1-28-07: Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HNBC-001): results from a multicenter, randomized controlled, open-label phase II trial
2024 · Dechuang Jiao, Jianghua Qiao, et al. · Cancer Research
Abstract PO1-27-05: De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER2-positive early breast cancer (HELEN-006):a randomized,phase 3 trial
2024 · Zhenzhen Liu, Xiuchun Chen, et al. · Cancer Research
Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HELEN-001): results from a multicenter, randomized controlled, open-label phase II trial
2024 · Zhenzhen Liu, Dechuang Jiao, et al. · Research Square
PDF
LncRNA SNHG16 modulates paclitaxel resistance in breast cancer by regulating Let-7a-5p/DUSP7
2023 · Hui Zhao, Lei Wang, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Investigation on the clinicopathological characteristics and BRCA1/2 gene variation of patients in breast cancer pedigrees in Northern Henan Province
2023 · Hui Zhao, Lei Wang, et al. · medRxiv
PDF
The clinical feature of triple-negative breast cancer in Beijing, China
2021 · Hui Zhao, Yueqing Feng, et al. · medRxiv
PDF
The Relationship Between the Expression of B7-H1/PD-1+in Breast Cancer and Micro-environment TILs and the Prognosis and the Molecular Typing
2016 · Liqin Yang, Yueqing Feng, et al. · Journal of pharmacy and pharmaceutical sciences
Biopsy of nonpalpable breast lesions aided by wire localization under the guidance of ultrasound
2011 · Yueqing Feng, Zhen-bin Xie, et al. · Central Plains Medical Journal
Fiberoptic ductoscopy in diagnosis of nipple discharge diseases
2009 · Yueqing Feng, Zhen-bin Xie, et al. · Central Plains Medical Journal
Works count: 19
Citation count: 45
H-index: 3
I10-index: 1
Year
Topic
Type